Kosan Biosciences
Founded | 1995 |
---|---|
Headquarters | Hayward, California |
Key people | Helen S. Kim (President & CEO) |
Number of employees | 90 |
Parent | Bristol Myers Squibb |
Kosan Biosciences, Inc. (stock symbol: KOSN), was a
Their technology platform was based on manipulation of the genetic instructions of microbes for making natural product polyketides. Rearranging the modular units in natural polyketide synthases, combining modules from different enzymes, and incorporating novel synthetic chemical starter units enabled them to produce a wide variety of novel polyketides that would be difficult to obtain via organic synthesis alone.[1]
Founded in 1995, Kosan was headquartered in
On June 26, 2008, Kosan Biosciences was acquired by
Discodermolide
Discodermolide is a recently discovered polyketide natural product found to be a potent inhibitor of tumor cell growth. Kosan had been working in conjunction with the Amos B. Smith research group on a preclinical drug development program.
Management
Helen S. Kim was the President & CEO of Kosan Biosciences in 2008 until it was sold to BMS.
References
- PMID 17317568.
- ^ https://www.cell.com/cell-chemical-biology/pdf/S1074-5521(02)00193-X.pdf
- ^ "BMS buys Kosan for $190M". Fierce Biotech. Retrieved 14 June 2022.
- ^ "Kosan Biosciences appoints Helen Kim". Biospace. Retrieved 14 June 2022.
- ^ "Helen Kim". IconOVir. Retrieved 14 June 2022.